Stockscreener 앱 받기
201.14
3.20%
-6.64
시간 외 거래:
201.14
전일 마감가:
$207.78
열려 있는:
$204.89
하루 거래량:
1.17M
Relative Volume:
0.97
시가총액:
$28.51B
수익:
$2.31B
순이익/손실:
$-208.16M
주가수익비율:
-130.90
EPS:
-1.5366
순현금흐름:
$76.11M
1주 성능:
+2.56%
1개월 성능:
+0.52%
6개월 성능:
+3.15%
1년 성능:
+35.39%
1일 변동 폭
$192.79
$204.93
1주일 범위
$192.79
$212.77
52주 변동 폭
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
명칭
Natera Inc
전화
650-249-9090
주소
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
201.14 | 29.11B | 2.31B | -208.16M | 76.11M | -1.5366 |
TMO
Thermo Fisher Scientific Inc
|
466.70 | 194.94B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
178.57 | 137.69B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.93 | 45.19B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.42 | 34.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
311.20 | 32.91B | 3.17B | 642.63M | 516.49M | 10.77 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | William Blair | Outperform |
| 2026-01-07 | 개시 | Citigroup | Buy |
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-10-27 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | 재개 | Wells Fargo | Equal Weight |
| 2025-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-08 | 재개 | Craig Hallum | Buy |
| 2024-02-20 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-11-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 개시 | Bernstein | Mkt Perform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 개시 | Stephens | Overweight |
| 2022-03-08 | 개시 | Goldman | Buy |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-09-28 | 개시 | Morgan Stanley | Overweight |
| 2020-09-17 | 개시 | SVB Leerink | Outperform |
| 2020-06-10 | 재개 | Piper Sandler | Overweight |
| 2020-05-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 개시 | JP Morgan | Neutral |
| 2018-07-05 | 재확인 | Piper Jaffray | Overweight |
| 2017-08-07 | 재확인 | Morgan Stanley | Overweight |
| 2016-11-10 | 재확인 | The Benchmark Company | Buy |
| 2016-05-23 | 재확인 | The Benchmark Company | Buy |
| 2016-05-11 | 재확인 | The Benchmark Company | Buy |
| 2016-04-19 | 개시 | The Benchmark Company | Buy |
| 2015-09-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2015-08-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 개시 | Robert W. Baird | Outperform |
| 2015-07-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 개시 | Piper Jaffray | Overweight |
| 2015-07-27 | 개시 | Wedbush | Neutral |
모두보기
Natera Inc 주식(NTRA)의 최신 뉴스
Natera, Inc. ($NTRA) CEO and President 2025 Pay Revealed - Quiver Quantitative
[ARS] Natera, Inc. SEC Filing - Stock Titan
Natera (NASDAQ: NTRA) details 2026 meeting agenda, pay votes and equity plan expansion - Stock Titan
Unveiling Natera (NTRA) Q4 outlook: Wall Street estimates for key metrics - MSN
Why (NTRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Is It Too Late To Consider Natera (NTRA) After Its Recent Share Price Surge? - simplywall.st
Natera (NTRA) Showcases Promising Evidence for Prospera Test at ISHLT Meeting - GuruFocus
17 transplant studies show Prospera flags earlier heart, lung warning signs - Stock Titan
Natera co-founder Sheena Jonathan sells $299,440 in shares By Investing.com - Investing.com South Africa
Natera co-founder Sheena Jonathan sells $299,440 in shares - Investing.com
Natera (NTRA) co-founder’s family trusts sell 1,500 shares under 10b5-1 plan - Stock Titan
Judge hands Natera 30% ongoing royalty in MRD patent battle - MSN
Natera positioned to capture growing $20 billion MRD opportunity: analyst - MSN
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA) - Yahoo Finance
3 Reasons We’re Fans of Natera (NTRA) - Yahoo Finance
Natera, Inc. (NTRA) Stock Analysis: A 23.78% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
Natera Sees RS Rating Improve To 76 - Investor's Business Daily
Court orders 30% ongoing royalty for Natera in patent dispute - MSN
Natera awarded 30% ongoing royalty in MRD patent litigation - MSN
Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know - Yahoo Finance
Cwm LLC Has $19 Million Holdings in Natera, Inc. $NTRA - MarketBeat
Natera, UFP Technologies, Mettler-Toledo, and Viatris shares are soaring, what you need to know - MSN
Chicago Capital LLC Purchases 12,805 Shares of Natera, Inc. $NTRA - MarketBeat
Natera, Inc. (NASDAQ:NTRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Natera (NASDAQ:NTRA) Rating Increased to Buy at Wall Street Zen - MarketBeat
Class Action Certification and CLARITY MRD Data Might Change The Case For Investing In Natera (NTRA) - simplywall.st
NTRA Technical Analysis | Trend, Signals & Chart Patterns | NATERA INC (NASDAQ:NTRA) - ChartMill
NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera (NTRA) Tops Q4 Earnings and Revenue Estimates - Eastern Progress
Is It Time To Reassess Natera (NTRA) After Its Mixed Share Price Performance? - simplywall.st
Barclays Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $280 - Moomoo
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates - MSN
Natera, Inc. (NASDAQ:NTRA) Short Interest Up 47.2% in March - MarketBeat
NTRA Initiated Coverage On by William Blair -- Rating Outperform - GuruFocus
NATERA INC : WILLIAM BLAIR INITIATES COVERAGE WITH OUTPERFORM RATING - Moomoo
Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst - Benzinga
Natera Inc stock (US6323071042): Is cell-free DNA testing strong enough to unlock sustained growth? - AD HOC NEWS
William Blair initiates coverage of Natera (NTRA) with outperform recommendation - MSN
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma - BioSpace
William Blair initiates Natera stock with Outperform on growth outlook - Investing.com
William Blair initiates Natera stock with Outperform on growth outlook By Investing.com - Investing.com India
Natera: Premium-Valued Leader in MRD Positioned for Long-Term Growth and Margin Expansion - TipRanks
Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Announce Pendency of Class Action Involving Purchasers of Natera, Inc. Common Stock - Eastern Progress
Lymphoma patients on Allogene therapy saw ctDNA drop 97.7% by Day 45 - Stock Titan
Natera, Inc. $NTRA Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
Moving Averages: Will Natera Inc benefit from sector rotation2026 Price Momentum & Daily Stock Trend Watchlist - baoquankhu1.vn
Natera Inc. (NTRA): Upside Potential Pulls Billionaire Stan Druckenmiller - MSN
Massachusetts Financial Services Co. MA Buys 20,927 Shares of Natera, Inc. $NTRA - MarketBeat
Aug Closing: Can Natera Inc outperform in the next rallyBull Run & AI Optimized Trade Strategies - baoquankhu1.vn
Assessing Natera (NTRA) Valuation After Patent Win Product Momentum And Upcoming Cancer Data - simplywall.st
Natera Inc (NTRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
8.29%
자본화:
|
볼륨(24시간):